Antibodies and other immunoreagents are so tied to lateral flow assays that we frequently use the terms LFA (lateral flow assay) and LFIA (lateral flow immunoassay) interchangeably. However, lateral flow assays may have no immunoreagents whatsoever onboard.
DCN Dx and QIAGEN Lake Constance are pleased to announce the second Rapid Testing Innovation Award. The award, which includes a cash prize of $10,000, will be presented at the 2019 Advanced Lateral Flow Course in October. The award recognizes the best innovation in rapid point-of-care assays or the most creative application for rapid assays during the past year.
When beginning any assay development program, you must consider a number of factors before you are on the road to a finished product. Between reagent selections, regulatory requirements, controls, sample collection, cassette design, and end user requirements, details can slip through the cracks. Even the smallest missed detail can halt progress and delay your development timeline.
Should you select monoclonal or polyclonal antibodies for your lateral flow rapid test? Some readers are probably wondering why polyclonal antibodies are not a thing of the past, like manual transmissions on cars and telephone landlines. However, the older models still have many advantages. This blog explores these advantages in the context of lateral flow assays.
The selection of the right antibody is key to creating a robust immunoassay that consistently provides reliable analytical information.
Innovative chemistry has developed several antibody labeling materials that can be used to modify antibodies to enhance their detectability. These antibody labeling materials include gold nanoparticles, colored cellulose particles, colored latex particles, magnetic particles, carbon nanoparticles, quantum dots, fluorophores and various enzymes.
DCN Dx has been recognized by Med Tech Outlook Magazine as a top 10 solution provider for in-vitro diagnostic technology for 2018. Read the exclusive article on Brendan O’Farrell, President & Founding Partner of DCN Dx here!
This article highlights the importance of designing a rapid diagnostic test for its intended purpose. Before going into the lab to develop an assay, one must start at the end and correctly identify the goals and use of the product. Only then can a point of care diagnostic device be designed correctly.
DCN Dx, in collaboration with Qiagen Lake Constance, is pleased to announce the first Rapid Testing Innovation Award, to be presented at the 2018 Advanced Lateral Flow Course in October. This competitive prize includes a cash award of $10,000 and will recognize the best innovation in the field of rapid point-of-care assays or the most novel application for rapid assays during the past year.